Keyphrases
Aldosterone Antagonists
12%
All-cause Mortality
37%
Cardiac Arrest
12%
Cardiovascular Hospitalizations
12%
Cardiovascular Mortality
12%
Clinical Outcomes
12%
Clinical Profile
12%
Comorbidity
12%
Hazard Ratio
12%
Heart Failure
12%
Heart Failure Treatment
12%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
HF Hospitalization
25%
Left Ventricular Ejection Fraction
12%
Mineralocorticoid Receptor Antagonists
12%
Non-cardiovascular
12%
Non-cardiovascular Mortality
12%
Outcome Effect
12%
Patient-reported Outcomes
12%
Patients with Heart Failure
12%
Placebo
12%
Placebo Treatment
12%
Preserved Systolic Function
12%
Prospective Evaluation
12%
Sex Differences
100%
Spironolactone
100%
Time-to-event Analysis
12%
TOPCAT
37%
TOPCAT Trial
100%
Treatment Effect
12%
Biochemistry, Genetics and Molecular Biology
Aldosterone
12%
All Cause Mortality
37%
Cardiac Arrest
12%
Cardiovascular Mortality
12%
Comorbidity
12%
Heart Ejection Fraction
100%
Heart Left Ventricle Ejection Fraction
12%
Mineralocorticoid
12%
Sex Difference
100%
Spironolactone
100%
Pharmacology, Toxicology and Pharmaceutical Science
Aldosterone Antagonist
12%
All Cause Mortality
37%
Cardiovascular Mortality
12%
Comorbidity
12%
Congestive Heart Failure
12%
Heart Arrest
12%
Heart Failure with Preserved Ejection Fraction
100%
Mineralocorticoid Antagonist
12%
Placebo
25%
Spironolactone
100%